S.Biomedics Co., Ltd. (KOSDAQ:304360)
South Korea flag South Korea · Delayed Price · Currency is KRW
17,310
+360 (2.12%)
At close: Jul 27, 2026

S.Biomedics Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-8,221-8,122-6,691-10,321-6,327-5,667
Depreciation & Amortization
2,2592,0431,7251,5531,5171,448
Loss (Gain) From Sale of Assets
----5.49--
Loss (Gain) From Sale of Investments
-78.26-105.87-25.23-51.81-6.77-0.24
Stock-Based Compensation
523.4442.3555.3886.21148.08217.39
Provision & Write-off of Bad Debts
234.46272.8412.67174.99-160.05-188.31
Other Operating Activities
-713.49482.881,8564,5643,1051,666
Change in Accounts Receivable
-935.47-155.49201.51-771.8-697.48440.6
Change in Inventory
506.35462.0271.14-830.05-817.71-204.21
Change in Accounts Payable
-169.82190.22-292.7363.31379.86-423.02
Change in Other Net Operating Assets
-669.92509.85-413.31-610.69-347.05-576.36
Operating Cash Flow
-7,264-3,981-3,500-6,149-3,205-3,287
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-4,672-4,604-1,390-1,847-9,295-474.49
Sale of Property, Plant & Equipment
---22.14--
Sale (Purchase) of Intangibles
-15-15-324.4--149.39-15.8
Investment in Securities
10,69010,582-8,547-6,6552,708-3,445
Other Investing Activities
81.63-563.05-86-343.25-43.69-64.87
Investing Cash Flow
6,0855,400-10,348-8,824-6,871-3,990

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-6,30011,775-7,0004,860
Total Debt Issued
6,3006,30011,775-7,0004,860
Long-Term Debt Repaid
--7,780-2,573-1,156-732.69-1,061
Total Debt Repaid
-7,668-7,780-2,573-1,156-732.69-1,061
Net Debt Issued (Repaid)
-1,368-1,4809,202-1,1566,2673,799
Issuance of Common Stock
807.591,6537,57414,282--
Other Financing Activities
-0-0133.5-808.56852.9362.18
Financing Cash Flow
-560.86173.3916,90912,3188,0204,161

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
26.448.3411.89-0.86-9.4759.35
Net Cash Flow
-1,7141,6013,074-2,656-2,066-3,057

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-11,936-8,584-4,890-7,996-12,501-3,762
Free Cash Flow Growth
------
Free Cash Flow Margin
-72.42%-51.88%-35.61%-61.00%-103.20%-42.42%
Free Cash Flow Per Share
-992.39-722.99-425.15-731.44-1223.19-370.56
Levered Free Cash Flow
-10,205-3,508-4,647-8,051-9,322-3,057
Unlevered Free Cash Flow
-9,298-2,602-4,150-7,499-8,867-2,636

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
373.84363.82426.59487.05156.16158.4
Cash Income Tax Paid
164.94176.067831.473.22-20.09
Change in Working Capital
-1,2691,007-433.4-2,149-1,482-762.99